All In Biotech

Drug Trial Radar · NCT05734482

Pharmacokinetic, Safety and Immunogenicity Study of CMAB015 and Cosentyx in Healthy Volunteers

Phase I Comparison of Pharmacokinetics, Safety, and Immunogenicity of CMAB015 Injection and Cosentyx in a Randomized, Double-blind, Parallel Controlled, Single-dose Study in Healthy Chinese Male Subjects

Last checked: Nov 19, 2026Latest source record: Apr 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 130 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

130

Actual

Start

Feb 15, 2023

Primary completion

Jul 3, 2023

Study completion Jul 3, 2023

Sponsor

Sponsor type
Industry
First posted
Feb 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, double-blinded, controlled Phase I study of CMAB015 administered by subcutaneous injection. This study will characterize the pharmacokinetic, safety and immunogenicity of CMAB015 versus Cosentyx(Secukinumab ) in healthy male subjects after a single dose.

Conditions

  • Psoriasis

Interventions

  • SecukinumabBiological

    for subcutaneous injection only

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Plasma Concentration-time Curve From Zero (0) Hours Extrapolated to infinite timeTime frame: up to 2688 hours
  2. Maximum Concentration of SecukinumabTime frame: up to 2688 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Second Hospital of Anhui Medical University

    Hefei, Anhui, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.